NASDAQ:ACOR - Acorda Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$19.89 +1.66 (+9.11 %)
(As of 10/17/2018 04:21 AM ET)
Previous Close$18.23
Today's Range$18.02 - $20.01
52-Week Range$15.60 - $36.35
Volume905,500 shs
Average Volume655,334 shs
Market Capitalization$933.06 million
P/E Ratio17.50
Dividend YieldN/A
Beta1.52
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ACOR
CUSIP00484M10
Phone914-347-4300

Debt

Debt-to-Equity Ratio0.56
Current Ratio4.09
Quick Ratio3.92

Price-To-Earnings

Trailing P/E Ratio17.50
Forward P/E Ratio
P/E GrowthN/A

Sales & Book Value

Annual Sales$588.29 million
Price / Sales1.61
Cash Flow$1.8033 per share
Price / Cash11.03
Book Value$11.12 per share
Price / Book1.79

Profitability

EPS (Most Recent Fiscal Year)$1.04
Net Income$-223,350,000.00
Net Margins-26.87%
Return on Equity8.19%
Return on Assets3.88%

Miscellaneous

Employees484
Outstanding Shares47,480,000
Market Cap$933.06 million

Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics Inc (NASDAQ:ACOR) posted its quarterly earnings data on Thursday, August, 2nd. The biopharmaceutical company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.90. The biopharmaceutical company earned $153.30 million during the quarter, compared to analysts' expectations of $138.63 million. Acorda Therapeutics had a negative net margin of 26.87% and a positive return on equity of 8.19%. The company's quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.29 EPS. View Acorda Therapeutics' Earnings History.

When is Acorda Therapeutics' next earnings date?

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, October 30th 2018. View Earnings Estimates for Acorda Therapeutics.

What price target have analysts set for ACOR?

13 analysts have issued 12 month price targets for Acorda Therapeutics' shares. Their predictions range from $13.00 to $37.00. On average, they anticipate Acorda Therapeutics' stock price to reach $23.3636 in the next year. This suggests a possible upside of 17.5% from the stock's current price. View Analyst Price Targets for Acorda Therapeutics.

What is the consensus analysts' recommendation for Acorda Therapeutics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acorda Therapeutics.

What are Wall Street analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:
  • 1. Cantor Fitzgerald analysts commented, ": We are reiterating our Neutral rating and $32 PT for ACOR. The company announced today that the US Court of Appeals has upheld a decision to invalidate four Ampyra patents, with the last remaining patent having expired on July 30, 2018. However, in our recent initiation on ACOR, we did not ascribe value to Ampyra due to the prior court rulings, which we predicted would be upheld on appeal. We anticipate a steep decline in Ampyra sales as generics now have an opportunity to enter the market, and this court decision may prompt generics to launch soon." (9/10/2018)
  • 2. HC Wainwright analysts commented, "We continue to expect generic erosion of the AMPYRA franchise in the coming months; however, we would also point out that oral arguments in Acorda’s appeal of the court decision to overturn the longest-lived AMPYRA patents have now been completed and the company continues to await a final decision. In the interim, Acorda has inked a conditional settlement agreement with Mylan N.V. (MYL; not rated) and affiliates over AMPYRA, pursuant to which Mylan would be permitted to market its generic version of Ampyra in the U.S. sometime in 2025 or earlier under certain circumstances. Investors should note that Acorda has also signed interim agreements with Teva Pharmaceutical Industries Ltd. (TEVA; not rated) and Hikma Pharmaceuticals PLC (HKMPY; not rated) concerning their patent litigation relating to AMPYRA." (8/6/2018)
  • 3. According to Zacks Investment Research, "Acorda is presently working on strengthening its Parkinson’s pipeline by focusing on the late stage candidate Inbrija in its portfolio. Inbrija’s NDA is under review in the United States and EU. Acorda boasts a strong pipeline addressing a wide range of disorders. The restructing initiative is also encuraging. The company’s share price has outperformed the industry so far this year. However, the company’s key multiple sclerosis drug Ampyra is expected to face generic competition from mid-2018 in the United States. Hence, Acorda’s dependence on Ampyra to draw major part of its revenues is concerning. Moreover, Inbrija received a refusal-to-file letter from the FDA for NDA for Inbrija last August. This in turn delayed its expected commercial launch, which was anticipated much earlier." (7/3/2018)

Who are some of Acorda Therapeutics' key competitors?

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the folowing people:
  • Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 62)
  • Mr. David Lawrence, Chief Technology officer, Chief of Bus. Operations & Principal Accounting Officer (Age 60)
  • Ms. Lauren M. Sabella, Chief Commercial Officer (Age 57)
  • Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 45)
  • Dr. Burkhard Blank, Chief Medical Officer (Age 63)

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Louisiana State Employees Retirement System (0.04%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence, Ian F Smith, Lauren M Sabella, Lorin Randall, Richard P Batycky, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.

Which institutional investors are selling Acorda Therapeutics stock?

ACOR stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. Company insiders that have sold Acorda Therapeutics company stock in the last year include Andrew A Hindman, Burkhard Blank, David Lawrence, Ian F Smith, Lauren M Sabella, Scopia Capital Management Lp and Steven M Rauscher. View Insider Buying and Selling for Acorda Therapeutics.

How do I buy shares of Acorda Therapeutics?

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $19.89.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $933.06 million and generates $588.29 million in revenue each year. The biopharmaceutical company earns $-223,350,000.00 in net income (profit) each year or $1.04 on an earnings per share basis. Acorda Therapeutics employs 484 workers across the globe.

What is Acorda Therapeutics' official website?

The official website for Acorda Therapeutics is http://www.acorda.com.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.


MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  333 (Vote Outperform)
Underperform Votes:  431 (Vote Underperform)
Total Votes:  764
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe ACOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel